SCHEMBL10077879

CC(=O)NC1C(O)[C@H](O[C@@H]2OC(CO[C@]3(C(=O)OCc4ccccc4)C[C@@H](O)[C@@H](C)C([C@H](O)[C@H](O)CO)O3)[C@H](O)[C@H](O)C2O)[C@H](CO)O[C@H]1OC1[C@@H](OCC2O[C@@H](O[C@@H]3C(CO)O[C@@H](O[C@@H]4C(CO)O[C@@H](CC(=O)CC(NC(=O)OCC5c6ccccc6-c6ccccc65)C(=O)O)C(NC(C)=O)[C@H]4O)C(NC(C)=O)[C@H]3O)C(O)[C@@H](O[C@H]3OC(CO)[C@@H](O)C(O)C3O[C@@H]3OC(CO)[C@@H](O[C@@H]4OC(CO[C@]5(C(=O)OCc6ccccc6)C[C@@H](O)[C@@H](C)C([C@H](O)[C@H](O)CO)O5)[C@H](O)[C@H](O)C4O)[C@H](O)C3NC(C)=O)[C@@H]2O)OC(CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.46

Predicted protein targets (top 3)

	gene	UniProt	supporting neighbours	confidence
▸	MAG	P20916	12/20	0.46

▸	SELE	P16581	5/20	0.43

▸	SIGLEC7	Q9Y286	2/20	0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL10077878	0.95	SIGLEC7 (0.47)	MAGSELESIGLEC7
SCHEMBL17540411	0.94	MAG (0.45)	MAGSELESIGLEC7
SCHEMBL10077911	0.89	MAG (0.50)	MAGSELESIGLEC7
SCHEMBL12239765	0.85	CD209 (0.43)	SELE
SCHEMBL12036219	0.85	CD209 (0.43)	SELE
SCHEMBL2629585	0.85	CD209 (0.43)	SELE
SCHEMBL13004038	0.85	SIGLEC7 (0.52)	MAGSELESIGLEC7
SCHEMBL12534286	0.85	SIGLEC7 (0.50)	MAGSELESIGLEC7
SCHEMBL16312034	0.83	CD209 (0.37)	MAGSELESIGLEC7
SCHEMBL14570808	0.82	SIGLEC7 (0.50)	MAGSELESIGLEC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-8507429-B2	Sugar chain added GLP-1 peptide	GLYTECH, INC. (JP)	2013-08-13	—	—	US	disclosed
US-8399656-B2	Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides	OTSUKA CHEMICAL CO., LTD. (JP)	2013-03-19	—	—	US	disclosed
US-20120035345-A1	PROCESS FOR PREPARING GLYCOPEPTIDES HAVING ASPARAGINE-LINKED OLIGOSACCHARIDES, AND THE GLYCOPEPTIDES	OTSUKA CHEMICAL CO., LTD. (JP)	2012-02-09	—	—	US	disclosed
US-20110245166-A1	SUGAR CHAIN ADDED GLP-1 PEPTIDE	OTSUKA CHEMICAL HOLDINGS CO., LTD (JP)	2011-10-06	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20110245166-A1	SUGAR CHAIN ADDED GLP-1 PEPTIDE	GLP1R, IAPP, GIPR	MAG 1836/4885SELE 158/4885SIGLEC7 308/4885
US-20120035345-A1	PROCESS FOR PREPARING GLYCOPEPTIDES HAVING ASPARAGINE-LINKED OLIGOSACCHARIDES, AND THE GLYCOPEPTIDES	ASNS, BSG, ANPEP	MAG 974/4885SELE 593/4885SIGLEC7 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.